Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cobalt-60 is a synthetic radioactive isotope of cobalt produced by neutron activation of stable cobalt-59 in nuclear reactors. It has a half-life of approximately 5.27 years and decays by beta emission to nickel-60, accompanied by the emission of high-energy gamma rays (1.17 MeV and 1.33 MeV). In medicine, cobalt-60 is primarily used as a radiopharmaceutical for external beam radiation therapy (teletherapy) to treat various cancers; its gamma rays are effective at destroying malignant cells. It is also widely used for sterilization of medical equipment and pharmaceuticals due to its strong gamma emissions that eliminate bacteria and pathogens. Industrial applications include non-destructive testing (NDT) for inspecting materials and structures as well as food irradiation to extend shelf life and ensure safety. Cobalt-60 does not occur naturally; it must be produced in nuclear reactors under controlled conditions[2][3][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cobalt-60.